The relentless, progressive nature of Type 2 diabetes results in an almost inevitable need for insulin supplementation and its intensification in an attempt to combat a worsening glycaemic profile 1,2, including glycaemic variability 3 and the associated increased risk of vascular complications 4–7. The gene discussed is INS; the disease is type 2 diabetes mellitus.